Samsung Biologics Co.,Ltd.
Bear Case (25th pct.)
-64.7% vs price
Base Case (Median)
-53.6% vs price
Bull Case (75th pct.)
-40.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $439812.28 | -66.0% | High (40%) |
| PE Comparable | $898982.91 | -30.6% | Medium (25%) |
| Growth Trajectory DCF | $2032622.96 | 57.0% | Medium (20%) |
| Graham Number | $383633.05 | -70.4% | Medium (40%) |
| EV/EBITDA | $601522.37 | -53.6% | Medium (20%) |
| EV/FCF | $631091.70 | -51.3% | Medium (20%) |
| Earnings Power Value | $474312.06 | -63.4% | Medium (50%) |
Based on 7 out of 8 methods, 207940.KS appears overvalued at the current price of $1295000.00. The base case fair value of $601522.37 implies 53.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.